Coronarin A

Coronarin A is an orally active natural compound that inhibits mTORC1 and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research^[1]. In Vitro: Coronarin A (3-30 μM; 4 or 12 h) stimulates glycogen synthesis through activating PI3K/Akt/GSK3β signaling and inhibits gluconeogenesis by activating ERK-dependent Wnt/β-catenin/TCF7L2 pathway in rat primary hepatocytes^[1].
Coronarin A (1-30 μM; 4 h) increases tyrosine phosphorylation of IRS1 through inhibiting mTOR/S6K1 signaling^[1]. In Vivo: Coronarin A (30 or 100 mg/kg; i.p. or p.o.; once daily for 22 days) ameliorates hyperglycemia in mice^[1].
Coronarin A (100 mg/kg; p.o.; once daily for 22 days) inhibits the mTOR/S6K1 pathway to activate PI3K/Akt and ERK/β-catenin signaling in livers of ob/ob mice^[1].
Pharmacokinetic properties of Coronarin A after single administration^a in ob/ob mice^[1].

Coronarin A	t1/2 (h)	tmax (h)	Cmax (ng/mL)	AUC0-t (ng·h/mL)	AUC0-∞ (ng·h/mL)	MRT (h)
i.p.	14.8	1.0	1073	4571	11045	21.7
p.o.	3.01	1.0	388	1694	1856	4.88

Data are presented as the mean of three mice.
^aCoronarin A was intraperitoneally or orally administered at 30 mg/kg to ob/ob mice.